Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | GSK3A | P49840 | 3/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.40 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14307966 | 0.86 | GSK3A (0.60) | LMNAGSK3ARPS6KA3MAPK14ABCB1 | |
| SCHEMBL12799297 | 0.85 | LMNA (0.54) | LMNAGSK3ARPS6KA3MAPK14ABCB1 | |
| SCHEMBL13084357 | 0.85 | LMNA (0.75) | LMNAGSK3ARPS6KA3MAPK14ABCB1 | |
| SCHEMBL13046095 | 0.85 | LMNA (0.75) | LMNAGSK3ARPS6KA3MAPK14ABCB1 | |
| SCHEMBL13863569 | 0.85 | LMNA (0.75) | LMNAGSK3ARPS6KA3MAPK14ABCB1 | |
| SCHEMBL14075778 | 0.85 | LMNA (0.75) | LMNAGSK3ARPS6KA3MAPK14ABCB1 | |
| SCHEMBL13084455 | 0.82 | LMNA (0.70) | LMNAGSK3ARPS6KA3MAPK14ABCB1 | |
| SCHEMBL14075786 | 0.81 | LMNA (0.66) | LMNAGSK3ARPS6KA3MAPK14ABCB1 | |
| SCHEMBL13084457 | 0.81 | LMNA (0.66) | LMNAGSK3ARPS6KA3MAPK14ABCB1 | |
| SCHEMBL14304184 | 0.79 | LMNA (0.64) | LMNAABCB1P2RX3P2RX4P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906518-B2 | [(3aR,4R,6R,6aR)-6-(6-amino-2-methoxy-9H-purin-9yl)tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]methanol; improved oral absorption | CBT DEVELOPMENT LIMITED (GB) | 2011-03-15 | — | — | US | disclosed |
| US-20080027081-A1 | Therapeutic compounds | BIOVITRUM AB (PUBL) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027081-A1 | Therapeutic compounds | ADORA2A, ADORA3, ADORA2B | LMNA 698/4885GSK3A 1187/4885RPS6KA3 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.